Search results for: 'medicine ad regenerative'

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

The Frost Radar™ for the demand-side platform (DSP) market assesses providers offering software solutions that enable advertisers and agencies to plan, buy, measure, execute, and optimize their global advertising initiatives. These platforms act as advertising demand aggregators that permit the acquisition of ad inventory from media supply sources,...

Precision diagnosis in today's healthcare is pivotal, tailoring treatment to individual patients based on genetic, molecular, and environmental factors. This targeted approach enhances accuracy, enables early detection and targeted treatment, minimizes trial-and-error treatment, and optimizes therapeutic outcomes. By leveraging advanced technol...

The healthcare industry is undergoing a massive transformation, with a high focus on personalization and patient-centric care. It is embracing digital transformation and becoming more consumer-/patient friendly. The changing socioeconomic landscape, the high prevalence of chronic diseases, the massive COVID-19 pandemic, and the challenge of resourc...

The automotive industry is among the most affected by the COVID-19 pandemic and the ongoing semiconductor shortage. The resulting economic crisis impacted overall vehicle sales, leading to a delay in value chain components supply and technology introduction and a shift in consumer preferences. Original equipment manufacturers (OEMs) and value ch...

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarke...

The medical imaging and informatics industry is evolving, with vendors launching new products and solutions every other day. As the reimbursement environment transitions from fee-for-service to value-based payment, vendors business models and value propositions are changing. New evidence on the use of specific imaging techniques is influencing chan...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...